(2023). Health economic impact of moderate-to-severe chronic pain associated with osteoarthritis in England: a retrospective analysis of linked primary and secondary care data. Bmj Open, 13, e067545. http://doi.org/10.1136/bmjopen-2022-067545
. T. Tritton
First name
T.
Last name
Tritton
(2023). Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England. Int J Chron Obstruct Pulmon Dis, 18, 1431-1444. http://doi.org/10.2147/copd.s411437
. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 18, 643-659. http://doi.org/10.2147/copd.s405498
. (2023). Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 18, 231-245. http://doi.org/10.2147/copd.s389281
. (2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis, 17, 2417-2429. http://doi.org/10.2147/copd.s370540
. (2022). Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England. Bmj Open Respir Res, 9. http://doi.org/10.1136/bmjresp-2022-001243
. (2022). Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 17, 1781-1795. http://doi.org/10.2147/copd.s365480
. (2021). Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK. Diabetes Obes Metab. http://doi.org/10.1111/dom.14580
. (2021). Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study. J Psychiatr Res. http://doi.org/10.1016/j.jpsychires.2021.05.026
.